Health
ENHERTU® Plus Pertuzumab Granted Priority Review in the U.S. as First-Line Treatment for Patients with HER2 Positive Metastatic Breast Cancer
TOKYO & BASKING RIDGE, N.J., September 24, 2025--ENHERTU Plus Pertuzumab Granted Priority Review in the U.S. as First-Line Treatment for Patients with HER2 Positive Metastatic Breast Cancer
About this update from Daiichi Sankyo Company, Limited
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":474,"url":"https://media.zenfs.com/en/business-wire.com/ca28fa85c25c68bbb5dc16cbcce3142d"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/iBpufjMilEgyDhk.tQ5YbQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTk0ODtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/ca28fa85c25c68bbb5dc16cbcce3142d","width":480,"height":474}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Based on DESTINY-Breast09 phase 3 trial results, which showed ENHERTU plus pertuzumab reduced the risk of disease progression or death by 44% versus THP with a median progression-free survival of greater than three years","length":220,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"If approved, Daiichi Sankyo and AstraZeneca’s ENHERTU-based treatment approach would move into the first-line HER2 positive metastatic setting with potential to become a new standard of care","length":190,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":410,"olType":false},{"type":"text","content":"TOKYO & BASKING RIDGE, N.J., September 24, 2025--(BUSINESS WIRE)--Daiichi Sankyo (TSE: 4568) and AstraZeneca’s (LSE/STO/Nasdaq: AZN) supplemental Biologics License Application (sBLA) for ENHERTU® (fam-trastuzumab deruxtecan-nxki) in combination with pertuzumab has been accepted and granted Priority Review in the U.S. for the first-line treatment of adult patients with unresectable or metastatic HER2 positive breast cancer.","length":430,"tagName":"p"},{"type":"text","content":"ENHERTU is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca.","length":195,"tagName":"p"},{"type":"text","content":"The U.S. Food and Drug Administration (FDA) grants Priority Review to applications for medicines that, if approved, would offer significant improvements over available treatment options by demonstrating safety or efficacy improvements, preventing serious conditions or enhancing patient compliance. The Priority Review follows receipt of Breakthrough Therapy Designation granted by the FDA for ENHERTU plus pertuzumab based on data from the DESTINY-Breast09 phase 3 tria...